TrustFinance is trustworthy and accurate information you can rely on. If you are looking for financial business information, this is the place for you. All-in-One source for financial business information. Our priority is our reliability.

TrustFinance Global Insights
Feb 04, 2026
2 min read
10

Arm Holdings projected fourth-quarter revenue above Wall Street estimates, driven by high demand for its artificial intelligence chip designs. The company forecast revenue of $1.47 billion, surpassing the average analyst estimate of $1.44 billion. However, its stock fell 6% in after-hours trading.
The optimistic forecast is fueled by the critical role of Arm's power-efficient chip designs in AI applications, which help manage energy costs in data centers and smartphones. Major tech companies like Nvidia utilize Arm’s architecture for AI-focused server chips, solidifying its position in the ecosystem. CEO Rene Haas noted that the benefits from AI sales have no end in sight.
The stock decline followed the release of fiscal third-quarter results, where licensing revenue was $505 million, slightly below estimates of $519.9 million. In contrast, total revenue for the quarter was $1.24 billion, beating expectations, and royalty revenue grew 27% to $737 million, also exceeding estimates.
Despite the slight miss on licensing fees, Arm's long-term outlook remains positive, supported by sustained and growing demand from the AI sector. The company's ability to capitalize on AI trends will be a key factor for investors to watch.
Q: Why did Arm's stock fall despite a strong revenue forecast?
A: The stock fell primarily because its third-quarter licensing revenue of $505 million slightly missed Wall Street estimates of $519.9 million.
Q: What is driving Arm's revenue growth?
A: Strong demand for its power-efficient chip designs, which are essential for artificial intelligence applications in data centers and consumer devices.
Source: Investing.com

TrustFinance Global Insights
AI-assisted editorial team by TrustFinance curating reliable financial and economic news from verified global sources.
Related Articles

04 Feb 2026
Generate Biomedicines Files for Nasdaq IPO